Abivax SA American Depositary Shares ABVX
i
Market datapartial · fetched 2026-11-06T20:59:31.457Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-13
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T20:59:29.500885766Z
FundamentalsAlpha Vantage · unavailable
Abivax SA American Depositary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 94.17 | 76.5% | 11.1% | 78.14 | 85.0% | 10.1% |
| 25Δ | 80.03 | 79.3% | 8.3% | |||
| 30Δ | 90.85 | 73.6% | 8.0% | 81.45 | 77.2% | 7.0% |
| 35Δ | 89.68 | 75.5% | 7.1% | 82.82 | 72.8% | 5.8% |
| 40Δ | 88.55 | 77.8% | 6.3% | 84.03 | 67.6% | 4.7% |
| 45Δ | 85.04 | 66.3% | 4.0% | |||
| 50Δ | 86.03 | 66.6% | 3.4% | |||
| 55Δ | 85.00 | 81.9% | 4.2% | 87.02 | 65.9% | 2.9% |
| 60Δ | 83.88 | 76.0% | 3.3% | 88.01 | 65.2% | 2.4% |
| 65Δ | 82.71 | 76.4% | 2.7% | 89.21 | 67.6% | 2.0% |
| 70Δ | 81.45 | 77.2% | 2.2% | 90.37 | 67.3% | 1.6% |
| 75Δ | 80.23 | 76.2% | 1.7% | 91.62 | 67.2% | 1.3% |
| 80Δ | 78.46 | 80.7% | 1.4% | 92.79 | 65.0% | 0.9% |
20Δ
- Pseudo strike
- 94.17
- IV
- 76.5%
- B/E move
- 11.1%
- Pseudo strike
- 78.14
- IV
- 85.0%
- B/E move
- 10.1%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 80.03
- IV
- 79.3%
- B/E move
- 8.3%
30Δ
- Pseudo strike
- 90.85
- IV
- 73.6%
- B/E move
- 8.0%
- Pseudo strike
- 81.45
- IV
- 77.2%
- B/E move
- 7.0%
35Δ
- Pseudo strike
- 89.68
- IV
- 75.5%
- B/E move
- 7.1%
- Pseudo strike
- 82.82
- IV
- 72.8%
- B/E move
- 5.8%
40Δ
- Pseudo strike
- 88.55
- IV
- 77.8%
- B/E move
- 6.3%
- Pseudo strike
- 84.03
- IV
- 67.6%
- B/E move
- 4.7%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 85.04
- IV
- 66.3%
- B/E move
- 4.0%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 86.03
- IV
- 66.6%
- B/E move
- 3.4%
55Δ
- Pseudo strike
- 85.00
- IV
- 81.9%
- B/E move
- 4.2%
- Pseudo strike
- 87.02
- IV
- 65.9%
- B/E move
- 2.9%
60Δ
- Pseudo strike
- 83.88
- IV
- 76.0%
- B/E move
- 3.3%
- Pseudo strike
- 88.01
- IV
- 65.2%
- B/E move
- 2.4%
65Δ
- Pseudo strike
- 82.71
- IV
- 76.4%
- B/E move
- 2.7%
- Pseudo strike
- 89.21
- IV
- 67.6%
- B/E move
- 2.0%
70Δ
- Pseudo strike
- 81.45
- IV
- 77.2%
- B/E move
- 2.2%
- Pseudo strike
- 90.37
- IV
- 67.3%
- B/E move
- 1.6%
75Δ
- Pseudo strike
- 80.23
- IV
- 76.2%
- B/E move
- 1.7%
- Pseudo strike
- 91.62
- IV
- 67.2%
- B/E move
- 1.3%
80Δ
- Pseudo strike
- 78.46
- IV
- 80.7%
- B/E move
- 1.4%
- Pseudo strike
- 92.79
- IV
- 65.0%
- B/E move
- 0.9%
Options history
Table
| Date | IV (%) |
|---|---|
| 75.67% | |
| 71.96% | |
| 64.87% | |
| 63.36% | |
| 64.52% | |
| 72.06% | |
| 68.27% | |
| 64.46% | |
| 68.76% | |
| 61.72% | |
| 60.67% | |
| 62.24% | |
| 60.22% | |
| 65.22% | |
| 57.58% | |
| 58.07% | |
| 58.42% | |
| 62.42% | |
| 62.77% | |
| 60.49% | |
| 76.48% | |
| 78.90% | |
| 81.26% | |
| 75.50% | |
| 82.43% | |
| 85.34% | |
| 89.46% | |
| 92.99% | |
| 82.47% | |
| 84.80% | |
| 66.72% | |
| 68.15% | |
| 64.25% | |
| 66.93% | |
| 65.18% | |
| 66.99% | |
| 63.98% | |
| 66.53% | |
| 62.77% | |
| 60.94% | |
| 64.40% | |
| 66.94% | |
| 72.04% | |
| 62.69% | |
| 66.94% | |
| 64.52% | |
| 69.43% | |
| 72.65% | |
| 69.87% | |
| 66.32% | |
| 66.81% | |
| 69.40% | |
| 71.42% | |
| 63.34% | |
| 67.56% | |
| 64.19% | |
| 65.68% | |
| 71.59% | |
| 62.22% |
Biotechnology
ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central…
More →ACET
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company is headquartered in Boston,…
More →ACHV
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and markets cytisinicline for smoking and nicotine addiction cessation in the United States and…
More →ACIU
AC Immune SA, a clinical-stage biopharmaceutical company, discovers, designs and develops drugs and diagnostic products for the prevention and treatment of neurodegenerative…
More →ACOG
Alpha Cognition Inc. is a pioneering biopharmaceutical firm dedicated to revolutionizing the treatment landscape for neurodegenerative diseases, with a primary focus on…
More →ACRS
Description unavailable
More →